KMCSHILKMC Speciality Hospitals (India) Ltd.

    KMC Speciality Hospitals (India) Q2 FY27 Results: Standalone Net Profit ₹16.22 Crore on Total Income of ₹94.39 Crore

    • Earnings
    • hospital services
    A long hospital corridor with cream walls, red stripes, closed doors and recessed ceiling lights.
    W.carter, via Wikimedia Commons (CC0). Illustrative image.

    KMC Speciality Hospitals (India) (NSE: KMCSHIL) reported total income of ₹94.39 crore and net profit of ₹16.22 crore on a standalone basis for the quarter ended 30 Sep 2026, it said in a filing on 13 Nov 2026.

    Key highlights

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹94.39 crore, up 24.0% YoY and 0.9% QoQ
    • Net profit and EPS: ₹16.22 crore, up 49.6% YoY and down 2.1% QoQ; basic EPS ₹0.99
    • Finance costs: ₹1.93 crore, down 5.6% YoY and 3.6% QoQ

    Summary

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    94.3976.15+24.0%93.58+0.9%
    16.2210.84+49.6%16.57-2.1%
    EPS, basic (₹)0.990.66+50.0%1.02-2.9%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Profit grew faster than income. Net profit rose 49.6% YoY against 24.0% growth in total income, and profit before tax rose 46.8%. Tax expense rose 38.9% to ₹5.42 crore, a slower pace than profit before tax, so the net margin widened to 17.19% from 14.24% a year earlier.

    Other income is small against the operating line. At ₹1.46 crore it is 1.5% of total income and 6.7% of profit before tax of ₹21.64 crore, so the quarter's profit rests mainly on revenue from operations of ₹92.94 crore. Other income fell 19.4% from the previous quarter's ₹1.81 crore.

    Finance costs are 2.0% of total income, at ₹1.93 crore, and fell from ₹2.05 crore a year earlier. Depreciation rose 16.7% YoY to ₹6.19 crore. Against the previous quarter, net profit eased 2.1% while total income rose 0.9%, and profit before tax fell 3.6%.

    The statement shows no exceptional items for the quarter. The statutory auditors, Deloitte Haskins & Sells, issued a limited review report that said nothing came to their attention requiring disclosure under Regulation 33 of the Listing Regulations.

    Inference

    The filing reports standalone results only, with a single segment of medical and healthcare services, and paid-up equity share capital of ₹16.31 crore at Re. 1 face value per share.

    The filing does not state the reason for the rise in revenue and profit, the reason for the rise in depreciation, or whether any dividend has been declared. These are not known from the filing.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts